Cara Therapeutics (CARA) Misses Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Janney Cuts Price Target on Cara Therapeutics (CARA) as UP is Delayed
March 11, 2016 10:12 AM ESTJanney Capital maintained a Buy rating on Cara Therapeutics (NASDAQ: CARA), and cut the price target to $18.00 (from $23.00), following the company's 4Q earnings report and conference call. The most significant development on the call was the disclosure that its December 2015 meeting with the FDA regarding its effort to develop CR845 for UP. Janney thought... More
